iShares Neuroscience and Healthcare ETF
IBRN
3 hedge funds and large institutions have $4.32M invested in iShares Neuroscience and Healthcare ETF in 2023 Q2 according to their latest regulatory filings, with 1 funds opening new positions, 0 increasing their positions, 1 reducing their positions, and closing their positions.
50% more funds holding
Funds holding: 2 → 3 (+1)
1% less capital invested
Capital invested by funds: $4.35M → $4.32M (-$24.6K)
2.19% less ownership
Funds ownership: 91.1% → 88.91% (-2.2%)
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 1
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
+$25 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FTUS
Flow Traders U.S.
New York
|
-$109K |
IBRN Hedge Fund Activity: Q2 2023 in Review
3 of the 6,383 institutional investors tracked by Wall St. Rank reported a position in iShares Neuroscience and Healthcare ETF (IBRN) for Q2 2023, worth a combined $4.32M — down 0.57% from $4.35M a quarter earlier.
Buyers outnumbered sellers: 1 fund opened new IBRN positions and 0 closed out — a net gain of 1 holder — while 0 added to existing stakes and 1 trimmed.
The largest buyer was UBS Group, opening a new position worth an estimated $25. The largest seller was Flow Traders U.S., cutting an estimated $109K.
- 3 institutional investors held iShares Neuroscience and Healthcare ETF (IBRN) as of Q2 2023, up from 2 in Q1 2023.
- Funds reported $4.32M of iShares Neuroscience and Healthcare ETF stock for Q2 2023, down 0.57% quarter-over-quarter.
- 1 fund opened new iShares Neuroscience and Healthcare ETF positions in Q2 2023 and 0 closed out, a net change of +1 holder.
- The largest iShares Neuroscience and Healthcare ETF buyer in Q2 2023 was UBS Group, an estimated $25 added.
- The largest iShares Neuroscience and Healthcare ETF seller in Q2 2023 was Flow Traders U.S., an estimated $109K sold.
Based on aggregated 13F filings for Q2 2023.